AstraZeneca PLC (NASDAQ:AZN) Position Increased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 57.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 181,601 shares of the company’s stock after acquiring an additional 66,181 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in AstraZeneca were worth $12,303,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Anchor Investment Management LLC acquired a new position in AstraZeneca during the fourth quarter worth $26,000. Compagnie Lombard Odier SCmA acquired a new position in AstraZeneca during the fourth quarter worth $27,000. Able Wealth Management LLC acquired a new position in AstraZeneca during the fourth quarter worth $27,000. Pin Oak Investment Advisors Inc. increased its position in AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after buying an additional 370 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in AstraZeneca by 86.7% during the fourth quarter. Jones Financial Companies Lllp now owns 506 shares of the company’s stock worth $34,000 after buying an additional 235 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on AZN shares. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Barclays raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. The Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They issued a “buy” rating and a $97.00 price target on the stock. Finally, Argus raised their price target on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $88.00.

AstraZeneca Stock Down 0.2 %

NASDAQ AZN opened at $77.99 on Friday. The firm has a market cap of $241.81 billion, a PE ratio of 38.23, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. AstraZeneca PLC has a one year low of $60.47 and a one year high of $80.86. The stock’s 50 day simple moving average is $77.52 and its 200 day simple moving average is $70.35. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.89 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.08. The business had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.